MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
February 02, 2024 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
OBI Logo.jpg
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
January 03, 2024 05:00 ET | OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...
OBI Logo.jpg
OBI-992 获FDA核准展开一/二期临床试验
January 03, 2024 05:00 ET | OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2为标靶、自行研发的抗体药物复合体(ADC)新药OBI-992,已获美国食品药物管理局(FDA)核准一/二期临床试验申请,以评估其安全性及疗效。 ...
OBI Logo.jpg
OBI-992 獲FDA核准展開一/二期臨床試驗
January 03, 2024 05:00 ET | OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2為標靶、自行研發的抗體藥物複合體(ADC)新藥OBI-992,已獲美國食品藥物管理局(FDA)核准一/二期臨床試驗申請,以評估其安全性及療效。 ...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
August 09, 2023 16:01 ET | MacroGenics, Inc.
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023 17:35 ET | MacroGenics, Inc.
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...